|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Russia
Espicom Business Intelligence Ltd, Oct 2011, Pages: 66
THE PHARMACEUTICAL MARKET: RUSSIA - REVIEW
Russia accounts for two-fifths of the total Central & Eastern European pharmaceutical market, due to its large GDP and population of 142 million; however, in per capita terms, Russia is also one of the smallest markets, comparing to Romania. The Russian pharmaceutical market is predicted to expand at a relatively high CAGR in US dollar terms over the next few years and will continue to be driven by import growth; a heavy reliance on imports has resulted from the lack of locally-manufactured innovative pharmaceuticals. Over the last few years, import growth has been boosted by the federal drug supply system (DLO). Around 80% of DLO funds are spent on imported pharmaceuticals.
The government is currently implementing the Pharma 2020 Strategy, which aims to encourage growth in the local pharmaceutical industry for the period up to 2020. Under the plan, the government will help local producers to cover the costs of the R&D that is required to boost production of innovative pharmaceuticals. It also hopes to create new companies that will be able to attract investment, create new jobs and produce competitive, safe, good quality, affordable products that fulfil the requirements of patients and the healthcare system. If the objectives of the plan are realised, by 2020, the local industry will be responsible for 50% of drugs in circulation, 80% of which will be innovative. The Strategy will require a lot of investment which will be sourced mainly from the federal budget, but the government is also trying to encourage international pharmaceutical companies to invest. So far, companies such as AstraZeneca, Novo Nordisk and Nycomed have made plans to invest in Russia.
The presence of foreign manufacturers is increasing in Russia. A number of agreements have been made in 2011 between domestic and foreign companies which will benefit the Russian pharmaceutical market. These include a joint venture between India's Aurobindo Pharma and Russia's OJSC Diod; a licensing agreement between Norgine and Nycomed that gives the latter exclusive rights to commercialise MoviPrep in Russia; investment by Rusnano, Russia’s government investment company, in Cleveland BioLabs' new subsidiary, Panacela Labs, which will develop a portfolio of new preclinical drug candidates in Russia; Pfizer and ChemRar High Technology Centre signing a memorandum of understanding to explore a collaboration focused on the research, development and commercialisation of innovative drugs in Russia; and the launching of Pro Bono Bio as a new international pharmaceutical company as a result of a three-year Anglo/Russian project.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
Customers who bought this item also bought
The Pharmaceutical Market: Pakistan
The Pharmaceutical Market: Turkey
The Pharmaceutical Market: Austria
The Pharmaceutical Market: Singapore
The Pharmaceutical Market: Vietnam
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Ukraine
The Pharmaceutical Market: Germany
The Pharmaceutical Market: Malaysia
The Pharmaceutical Market: Estonia
|
|
|
|
